PLUVICTO™ is the first and only approved PSMA-targeted radioligand therapy (RLT) that significantly extends survival in PSMA+ mCRPC patients.
PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Select patients for treatment using approved PSMA-11 PET imaging agent based on PSMA expression in tumors. We offer both PET Ga68 and F18 based PSMA-11 scans.
PLUVICTO™ is administered as solution for infusion given over 30 minutes every 6 weeks for up to 6 treatments, or until disease progression, or unacceptable toxicity.
The PSMA-targeted Radioligand Therapy (RLT) delivers DNA-breaking radiation directly to PSMA+ bone, nodal, and visceral metastases.
To get a referral for PLUVICTO™, please download and fill out the form below and return it to your provider.